Reintroduction of imatinib in GIST

about

Get the GIST? An overview of gastrointestinal stromal tumours.CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT.

P2860

Q38718860-AF27185C-C544-4534-8BA6-BE1555439791 Q49248913-01768CBE-2975-491B-ADFB-5D348BE1E21B

P2860

Reintroduction of imatinib in GIST

Item

http://www.wikidata.org/entity/Q37301364

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reintroduction of imatinib in GIST

@en

Reintroduction of imatinib in GIST.

@nl

type

Item

label

Reintroduction of imatinib in GIST

@en

Reintroduction of imatinib in GIST.

@nl

prefLabel

Reintroduction of imatinib in GIST

@en

Reintroduction of imatinib in GIST.

@nl

P1476

Reintroduction of imatinib in GIST

@en

P2093

T Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).

Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.

Gastrointestinal stromal tumours: origin and molecular oncology.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

P2888

s12029-013-9532-4

P304

385-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S12029-013-9532-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255694296

http://www.w3.org/2001/XMLSchema#string

P698

23921604

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

gastrointestinal stromal tumor

amide

hydrocarbon

local neoplasm recurrence

P932

3825279

http://www.w3.org/2001/XMLSchema#string

Reintroduction of imatinib in GIST

about

P2860

P2860

Reintroduction of imatinib in GIST

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932